Imagion Biosystems

Executive Summary

Imagion Biosystems is an Australian molecular imaging company developing MagSense™, a novel magnetic resonance imaging platform that uses bio-safe magnetic nanoparticles functionalized with cancer-specific targeting ligands. The technology enables non-radioactive, high-resolution detection of cancers such as HER2-positive breast, PSMA-positive prostate, and folate-receptor-positive ovarian cancer. By shifting cancer diagnosis from suspicion to certainty, MagSense aims to reduce unnecessary biopsies and enable earlier treatment. The company is currently in Phase 2 clinical development, leveraging its proprietary mMRI technology to address significant unmet needs in oncology imaging. With a strong IP portfolio and a differentiated approach that avoids the use of radioactive tracers, Imagion Biosystems has the potential to transform cancer diagnostics and improve patient outcomes. The platform's versatility also positions it for expansion into other cancer types and therapeutic monitoring applications, offering a scalable pipeline beyond its initial indications.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for MagSense in HER2-positive breast cancer60% success
• Q2 2027FDA breakthrough therapy designation for MagSense platform40% success
• H1 2027Strategic partnership or licensing deal with major pharmaceutical company50% success